(EBM) Eastwood Bio-Medical Canada - Ratings and Ratios

Eastwood Bio-Medical Canada Inc. (V:EBM) specializes in the marketing and distribution of natural health products under the Eleotin brand, targeting metabolic disorders such as blood glucose imbalances, hypertension, and obesity. Its product portfolio includes Eleotin A 700 for spleen deficiency, Eleotin AL88 as a laxative, Eleotin Cal20 for bone and teeth health, Eleotin V3D for bone and teeth development, Eleotin G2000 for cardiovascular health, Eleotin H55 for sedation and tension relief, and Eleotin Zn330 for tissue formation and metabolism. Additionally, Eleotin Bentley supports healthy glucose levels, while Eleotin LBM is designed for hypertension relief. The company, established in 2010 and headquartered in Richmond, Canada, operates as a subsidiary of Eastwood Bio-Medical Research Inc. and maintains a strong presence in Canada, the U.S., and Asia.

From a technical standpoint, EBMs stock shows a last price of $0.59, with short-term moving averages (SMA20 and SMA50) at $0.49 and a longer-term SMA200 at $0.62. The average trading volume over 20 days is 1235 shares, indicating limited liquidity. The ATR of $0.02 reflects low price volatility.

On the fundamental side, the company has a market cap of $40.64M CAD. The P/B ratio of 2942.82 suggests a significant disconnect between book value and market value. The P/S ratio of 62.19 indicates a premium valuation relative to sales. Notably, the return on equity (RoE) stands at 42.45%, highlighting profitable operations despite the elevated valuations.